Homology Medicines, Inc. (NASDAQ:FIXX) Receives $8.73 Average Target Price from Analysts

Posted by Defense World Staff on Jul 22nd, 2023

Homology Medicines, Inc. (NASDAQ:FIXX – Get Free Report) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.73.

A number of research analysts recently issued reports on the stock. FIX decreased their price target on shares of Homology Medicines from $19.00 to $7.00 in a research note on Thursday, April 6th. Chardan Capital restated a “buy” rating on shares of Homology Medicines in a research note on Monday, July 10th.

Homology Medicines Trading Down 4.6 %

FIXX stock opened at $1.04 on Wednesday. The business’s fifty day moving average price is $0.98 and its 200 day moving average price is $1.17. Homology Medicines has a 12-month low of $0.80 and a 12-month high of $3.30. The company has a market capitalization of $60.10 million, a PE ratio of -0.47 and a beta of -0.08.

Homology Medicines (NASDAQ:FIXX – Get Free Report) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $1.35 million. Homology Medicines had a negative net margin of 3,926.25% and a negative return on equity of 64.66%. Research analysts predict that Homology Medicines will post -1.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Raymond James & Associates purchased a new position in shares of Homology Medicines during the 1st quarter worth approximately $51,000. BlackRock Inc. increased its position in Homology Medicines by 7.9% during the first quarter. BlackRock Inc. now owns 3,869,946 shares of the company’s stock worth $11,765,000 after buying an additional 282,169 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Homology Medicines by 19.1% in the first quarter. Dimensional Fund Advisors LP now owns 328,446 shares of the company’s stock worth $998,000 after acquiring an additional 52,759 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Homology Medicines by 60.3% in the first quarter. Renaissance Technologies LLC now owns 234,000 shares of the company’s stock valued at $711,000 after acquiring an additional 88,007 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Homology Medicines by 17.1% during the first quarter. State Street Corp now owns 990,911 shares of the company’s stock valued at $3,012,000 after acquiring an additional 144,566 shares during the last quarter. 32.59% of the stock is owned by hedge funds and other institutional investors.

Homology Medicines Company Profile

(Get Free Report

Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders.